Insider · CIK 0001939159
Rene Bernards
Files at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). First filing -, latest -.
In brief
Rene Bernards files SEC Form 4 as director at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Rene Bernards has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +10,000 | $0.00 | $0 | 10,000 | Jul 8, 2025 |
| Jun 30, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +10,662 | $0.00 | $0 | 10,662 | Jul 8, 2025 |
| Mar 31, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +8,045 | $0.00 | $0 | 8,045 | Apr 2, 2025 |
| Jan 20, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +4,166 | $0.00 | $0 | 4,166 | Jan 22, 2025 |
| Sep 30, 2024 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +5,304 | $0.00 | $0 | 5,304 | Oct 29, 2024 |
Questions about Rene Bernards
Answered from the filings on this page, as of the latest one.
Is Rene Bernards buying or selling?
Rene Bernards has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Rene Bernards's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rene Bernards has 0.
Where does Rene Bernards file Form 4?
Rene Bernards has filed Form 4 at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.